


a
Antitumor Activity of Anti-LAG-3 and Anti-PD-1 Antibodies in Murine Models
Sa1N Fibrosarcoma
Control
Anti-LAG-3
Anti-PD-1
Anti-LAG-3 + Anti-PD-1
Tumor free: 0/10
Tumor free: 0/10
Tumor free: 2/10
Tumor free: 7/10
Tumor volume (mm3/2)
Time after inoculation (d)
b
MC38
Control
Anti-LAG-3
Anti-PD-1
Anti-LAG-3 + Anti-PD-1
Tumor free: 0/10
Tumor free: 0/10
Tumor free: 4/10
Tumor free: 8/10
Tumor volume (mm3/2)
Time after inoculation (d)

Fig. 1


Study Schematic



ICMARs = immune cell-modulating antibody regimens (such as, but not limited to, ipilimumab, tremelimumab, anti–PD-1, anti–PD-L1, anti–PD-L2, anti-KIR, anti-CD137, and/or anti-OX40 antibodies)

Fig. 2A


Study Schematic



ICMARs = immune cell-modulating antibody regimens (such as, but not limited to, ipilimumab, tremelimumab, anti–PD-1, anti–PD-L1, anti–PD-L2, anti-KIR, anti-CD137, and/or anti-OX40 antibodies)

Fig. 2B

Study Schematic for Parts A, B, and C



Diagnostic imaging to be performed every 12 weeks until progression in subjects who discontinue due to CR and in subjects with PR at the end of Cycle 12.
For treatment visits where both BMS-986016 and nivolumab are administered, nivolumab will be administered first, followed by BMS-986016 within 30 minutes after completion of the nivolumab infusion.

Fig. 3